系统性红斑狼疮患者血清B淋巴细胞刺激因子的变化及其临床意义

Clinical significance of serum B lymphocyte stimulator level in patients with systemic lupus erythematosus

目的观察免疫抑制治疗后,系统性红斑狼疮(SLE)患者血清B淋巴细胞刺激因子(Blys)的变化与疾病活动的关系。方法选取29例新确诊SLE患者,治疗前及经以强的松联合环磷酰胺冲击治疗为基础的免疫抑制治疗后1个月留取血标本,ELISA法检测血IgG、Blys、抗ds-DNA抗体滴度;治疗前后评估疾病活动指数(SLEADI)。结果治疗前患者血清Blys水平与SLEADI、血IgG、抗ds-DNA抗体滴度显著正相关。免疫抑制治疗后,患者血清Blys明显下降,Blys下降程度与患者SLEADI缓解程度显著相关;活动组患者血清Blys水平较缓解组显著降低。结论免疫抑制后SLE患者血清Blys显著下降,其下降程度与SLEADI缓解呈正相关。提示血清Blys水平有望成为判断免疫抑制治疗是否敏感以及评估病情活动的指标。

Objective To observe the change of serum B lymphocyte stimulator in systemic lupus erythematosus patients after immunosuppression treatment and it＇s correlation with disease activity. Methods Selected 29 newly diagnosed systemic lupus erythematosus patients. Blood samples were drawn and SLEDAI was analyzed before and after immunosuppression treatment. ELISA was employed to determine serum Blys, IgG and anti-dsDNA antibody. The correlation of serum Blys and SLEDAI, serum IgG, anti- dsDNA antibody were analyzed. Results Serum Blys was positively correlated with SLEADI, serum IgG and anti-dsDNA antibody in SLE patents before immunosuppression treatment. After immunosuppression treatment, serum Blys was markedly decreased; the change of serum Blys was positively correlated with the change of SLEADI. Serum Blys in active group was markedly higher than that of inactive group. Conclusion Serum Blys in SLE patients decreases significantly after immunosuppression treatment, which is positively correlated with the decrease of SLEDAI. These results suggest that serum Blys might be a new item for the determination of SLE disease activity and evaluation of therapy.